Effects of fucoidan on proliferation, AMP-activated protein kinase, and downstream metabolism- and cell cycle-associated molecules in poorly differentiated human hepatoma HLF cells

International Journal of Oncology

Volumn 46, Issue 5, 2015, Pages 2216-2222

  Kawaguchi, Takumi ^a,b   Hayakawa, Masako ^b   Koga, Hironori ^a,b   Torimura, Takuji ^a,b  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KURUME UNIVERSITY   (Japan)

Author keywords

Acetyl CoA carboxylase; AMP activated protein kinase; Cyclin D1; Fucoidan; Hepatocellular carcinoma

Indexed keywords

ACETYL COENZYME A CARBOXYLASE; ADENOSINE TRIPHOSPHATE CITRATE SYNTHASE; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; FUCOIDIN; GLYCOGEN SYNTHASE KINASE 3BETA; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATE BUFFERED SALINE; PROTEIN P53; TUBERIN; ANTINEOPLASTIC AGENT; POLYSACCHARIDE;

ARTICLE; CANCER CELL LINE; CANCER INHIBITION; CELL CYCLE; CELL CYCLE PROGRESSION; CELL METABOLISM; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; FATTY ACID SYNTHESIS; FLUORESCENCE ACTIVATED CELL SORTER; G1 PHASE CELL CYCLE CHECKPOINT; HEPATOMA CELL; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LIVER CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; DRUG EFFECTS; LIVER TUMOR; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

AMP-ACTIVATED PROTEIN KINASES; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; IMMUNOBLOTTING; LIVER NEOPLASMS; POLYSACCHARIDES;

EID: 84925423500     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2015.2928     Document Type: Article

References (37)

1. Burroughs A, Hochhauser D and Meyer T: Systemic treatment and liver transplantation for hepatocellular carcinoma: Two ends of the therapeutic spectrum. Lancet Oncol 5: 409-418, 2004.
2. Kluger MD, Salceda JA, Laurent A, Tayar C, Duvoux C, Decaens T, Luciani A, Van Nhieu JT, Azoulay D and Cherqui D: Liver resection for hepatocellular carcinoma in 313 western patients: tumor biology and underlying liver rather than tumor size drive prognosis. J Hepatol: Dec 18, 2014 (Epub ahead of print).
3. Tanaka K and Sorai S: Hydrolysis of fucoidan by abalone liver alpha-L-fucosidase. FEBS Lett 9: 45-48, 1970.
4. Cui W, Zheng Y, Zhang Q, Wang J, Wang L, Yang W, Guo C, Gao W, Wang X and Luo D: Low-molecular-weight fucoidan protects endothelial function and ameliorates basal hypertension in diabetic Goto-Kakizaki rats. Lab Invest 94: 382-393, 2014.
5. Fitton JH: Therapies from fucoidan; multifunctional marine polymers. Mar Drugs 9: 1731-1760, 2011.
6. Boo HJ, Hong JY, Kim SC, Kang JI, Kim MK, Kim EJ, Hyun JW, Koh YS, Yoo ES, Kwon JM, et al: The anticancer effect of fucoidan in PC-3 prostate cancer cells. Mar Drugs 11: 2982-2999, 2013.
7. Kim EJ, Park SY, Lee JY and Park JH: Fucoidan present in brown algae induces apoptosis of human colon cancer cells. BMC Gastroenterol 10: 96, 2010.
8. Xue M, Ge Y, Zhang J, Wang Q, Hou L, Liu Y, Sun L and Li Q: Anticancer properties and mechanisms of fucoidan on mouse breast cancer in vitro and in vivo. PLoS One 7: e43483, 2012.
9. Min EY, Kim IH, Lee J, Kim EY, Choi YH and Nam TJ: The effects of fucodian on senescence are controlled by the p16INK4a-pRb and p14Arf-p53 pathways in hepatocellular carcinoma and hepatic cell lines. Int J Oncol 45: 47-56, 2014.
10. Yuan HD and Piao GC: An active part of Artemisia sacrorum Ledeb. suppresses gluconeogenesis through AMPK mediated GSK3β and CREB phosphorylation in human HepG2 cells. Biosci Biotechnol Biochem 75: 1079-1084, 2011.
11. Roshan S, Liu YY, Banafa A, Chen HJ, Li KX, Yang GX, He GY and Chen MJ: Fucoidan induces apoptosis of HepG2 cells by down-regulating p-Stat3. J Huazhong Univ Sci Technolog Med Sci 34: 330-336, 2014.
12. Zhu C, Cao R, Zhang SX, Man YN and Wu XZ: Fucoidan inhibits the growth of hepatocellular carcinoma independent of angiogenesis. Evid Based Complement Alternat Med 2013: 692549, 2013.
13. Nagamine T, Hayakawa K, Kusakabe T, Takada H, Nakazato K, Hisanaga E and Iha M: Inhibitory effect of fucoidan on Huh7 hepatoma cells through downregulation of CXCL12. Nutr Cancer 61: 340-347, 2009.
14. Fukahori S, Yano H, Akiba J, Ogasawara S, Momosaki S, Sanada S, Kuratomi K, Ishizaki Y, Moriya F, Yagi M, et al: Fucoidan, a major component of brown seaweed, prohibits the growth of human cancer cell lines in vitro. Mol Med Rep 1: 537-542, 2008.
15. Hardie DG: AMPK - sensing energy while talking to other signaling pathways. Cell Metab 20: 939-952, 2014.
16. Lacher MD, Pincheira R, Zhu Z, Camoretti-Mercado B, Matli M, Warren RS and Castro AF: Rheb activates AMPK and reduces p27Kip1 levels in Tsc2-null cells via mTORC1-independent mechanisms: Implications for cell proliferation and tumorigenesis. Oncogene 29: 6543-6556, 2010.
17. Motoshima H, Goldstein BJ, Igata M and Araki E: AMPK and cell proliferation - AMPK as a therapeutic target for atherosclerosis and cancer. J Physiol 574: 63-71, 2006.
18. Hashimoto O, Shinkawa M, Torimura T, Nakamura T, Selvendiran K, Sakamoto M, Koga H, Ueno T and Sata M: Cell cycle regulation by the Wee1 inhibitor PD0166285, pyrido [2,3-d] pyimidine, in the B16 mouse melanoma cell line. BMC Cancer 6: 292, 2006.
19. Kawaguchi T, Yoshida T, Harada M, Hisamoto T, Nagao Y, Ide T, Taniguchi E, Kumemura H, Hanada S, Maeyama M, et al: Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3. Am J Pathol 165: 1499-1508, 2004.
20. Selvendiran K, Koga H, Ueno T, Yoshida T, Maeyama M, Torimura T, Yano H, Kojiro M and Sata M: Luteolin promotes degradation in signal transducer and activator of transcription 3 in human hepatoma cells: An implication for the antitumor potential of flavonoids. Cancer Res 66: 4826-4834, 2006.
21. Kawaguchi T, Sakisaka S, Mitsuyama K, Harada M, Koga H, Taniguchi E, Sasatomi K, Kimura R, Ueno T, Sawada N, et al: Cholestasis with altered structure and function of hepatocyte tight junction and decreased expression of canalicular multispecific organic anion transporter in a rat model of colitis. Hepatology 31: 1285-1295, 2000.
22. Matsumoto A, Ono M, Fujimoto Y, Gallo RL, Bernfield M and Kohgo Y: Reduced expression of syndecan-1 in human hepatocellular carcinoma with high metastatic potential. Int J Cancer 74: 482-491, 1997.
23. Yamamoto T, Nagano H, Sakon M, Wada H, Eguchi H, Kondo M, Damdinsuren B, Ota H, Nakamura M, Wada H, et al: Partial contribution of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway to antitumor effects of interferon-alpha/5-fluorouracil against hepatocellular carcinoma. Clin Cancer Res 10: 7884-7895, 2004.
24. Park HY, Kim GY, Moon SK, Kim WJ, Yoo YH and Choi YH: Fucoidan inhibits the proliferation of human urinary bladder cancer T24 cells by blocking cell cycle progression and inducing apoptosis. Molecules 19: 5981-5998, 2014.
25. Leprivier G, Remke M, Rotblat B, Dubuc A, Mateo AR, Kool M, Agnihotri S, El-Naggar A, Yu B, Somasekharan SP, et al: The eEF2 kinase confers resistance to nutrient deprivation by blocking translation elongation. Cell 153: 1064-1079, 2013.
26. Lee H, Kim JS and Kim E: Fucoidan from seaweed Fucus vesiculosus inhibits migration and invasion of human lung cancer cell via PI3K-Akt-mTOR pathways. PLoS One 7: e50624, 2012.
27. Migita T, Okabe S, Ikeda K, Igarashi S, Sugawara S, Tomida A, Taguchi R, Soga T and Seimiya H: Inhibition of ATP citrate lyase induces an anticancer effect via reactive oxygen species: AMPK as a predictive biomarker for therapeutic impact. Am J Pathol 182: 1800-1810, 2013.
28. Hopkins TA, Dyck JR and Lopaschuk GD: AMP-activated protein kinase regulation of fatty acid oxidation in the ischaemic heart. Biochem Soc Trans 31: 207-212, 2003.
29. Scaglia N, Chisholm JW and Igal RA: Inhibition of stearoylCoA desaturase-1 inactivates acetyl-CoA carboxylase and impairs proliferation in cancer cells: Role of AMPK. PLoS One 4: e6812, 2009.
30. Chang NW, Wu CT, Chen DR, Yeh CY and Lin C: High levels of arachidonic acid and peroxisome proliferator-activated receptor-alpha in breast cancer tissues are associated with promoting cancer cell proliferation. J Nutr Biochem 24: 274-281, 2013.
31. Hadad SM, Hardie DG, Appleyard V and Thompson AM: Effects of metformin on breast cancer cell proliferation, the AMPK pathway and the cell cycle. Clin Transl Oncol 16: 746-752, 2014.
32. Lin VC, Tsai YC, Lin JN, Fan LL, Pan MH, Ho CT, Wu JY and Way TD: Activation of AMPK by pterostilbene suppresses lipogenesis and cell-cycle progression in p53 positive and negative human prostate cancer cells. J Agric Food Chem 60: 6399-6407, 2012.
33. Rattan R, Giri S, Hartmann LC and Shridhar V: Metformin attenuates ovarian cancer cell growth in an AMP-kinase dispensable manner. J Cell Mol Med 15: 166-178, 2011.
34. Santra MK, Wajapeyee N and Green MR: F-box protein FBXO31 mediates cyclin D1 degradation to induce G1 arrest after DNA damage. Nature 459: 722-725, 2009.
35. Sikka A, Kaur M, Agarwal C, Deep G and Agarwal R: Metformin suppresses growth of human head and neck squamous cell carcinoma via global inhibition of protein translation. Cell Cycle 11: 1374-1382, 2012.
36. Zi FM, He JS, Li Y, Wu C, Yang L, Yang Y, Wang LJ, He DH, Zhao Y, Wu WJ, et al: Metformin displays anti-myeloma activity and synergistic effect with dexamethasone in in vitro and in vivo xenograft models. Cancer Lett 356: 443-453, 2015.
37. Banafa AM, Roshan S, Liu YY, Chen HJ, Chen MJ, Yang GX and He GY: Fucoidan induces G1 phase arrest and apoptosis through caspases-dependent pathway and ROS induction in human breast cancer MCF-7 cells. J Huazhong Univ Sci Technolog Med Sci 33: 717-724, 2013.